Pfizer Animal Health completes purchase
Pfizer Animal Health completed its acquisition of Synbiotics Corp. (Pinksheets SYNB.PK) Dec. 30, resulting in the cessation of trading of Synbiotics common stock. Shareholders of record of Synbiotics’ common stock will receive written instructions, including a letter of transmittal, for exchanging their stock for the merger consideration.
Pfizer Animal Health announced Dec. 29 that it was acquiring Synbiotics, a leader in the development, manufacture and marketing of immunodiagnostic tests for companion and food production animals.
According to a news release, the acquisition allows Pfizer Animal Health to enhance its offerings to veterinarians at point of care in the clinic and on the farm, and to expand into products for diagnostic reference laboratories and reproductive services for canine breeders.
“Our acquisition of Synbiotics, with its best-in-class product portfolio, promising research and development pipeline and manufacturing capability, will bring Pfizer Animal Health closer to its goal of becoming a comprehensive solutions provider to the animal health industry," said Juan Ramon Alaix, president, Pfizer Animal Health.